0001626644 2025-08-01 2026-01-31 0001626644 2026-03-11 0001626644 2026-01-31 0001626644 2025-07-31 0001626644 2025-11-01 2026-01-31 0001626644 2024-11-01 2025-01-31 0001626644 2024-08-01 2025-01-31 0001626644 us-gaap:CommonStockMember 2025-07-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2025-07-31 0001626644 us-gaap:RetainedEarningsMember 2025-07-31 0001626644 us-gaap:CommonStockMember 2025-10-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2025-10-31 0001626644 us-gaap:RetainedEarningsMember 2025-10-31 0001626644 2025-10-31 0001626644 us-gaap:CommonStockMember 2024-07-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2024-07-31 0001626644 us-gaap:RetainedEarningsMember 2024-07-31 0001626644 2024-07-31 0001626644 us-gaap:CommonStockMember 2024-10-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001626644 us-gaap:RetainedEarningsMember 2024-10-31 0001626644 2024-10-31 0001626644 us-gaap:CommonStockMember 2025-08-01 2025-10-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2025-08-01 2025-10-31 0001626644 us-gaap:RetainedEarningsMember 2025-08-01 2025-10-31 0001626644 2025-08-01 2025-10-31 0001626644 us-gaap:CommonStockMember 2025-11-01 2026-01-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2025-11-01 2026-01-31 0001626644 us-gaap:RetainedEarningsMember 2025-11-01 2026-01-31 0001626644 us-gaap:CommonStockMember 2024-08-01 2024-10-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2024-08-01 2024-10-31 0001626644 us-gaap:RetainedEarningsMember 2024-08-01 2024-10-31 0001626644 2024-08-01 2024-10-31 0001626644 us-gaap:CommonStockMember 2024-11-01 2025-01-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-01-31 0001626644 us-gaap:RetainedEarningsMember 2024-11-01 2025-01-31 0001626644 us-gaap:CommonStockMember 2026-01-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2026-01-31 0001626644 us-gaap:RetainedEarningsMember 2026-01-31 0001626644 us-gaap:CommonStockMember 2025-01-31 0001626644 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0001626644 us-gaap:RetainedEarningsMember 2025-01-31 0001626644 2025-01-31 0001626644 ODYY:DerivativeLiabilityMember us-gaap:FairValueInputsLevel1Member 2026-01-31 0001626644 ODYY:DerivativeLiabilityMember us-gaap:FairValueInputsLevel2Member 2026-01-31 0001626644 ODYY:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2026-01-31 0001626644 ODYY:DerivativeLiabilityMember 2026-01-31 0001626644 ODYY:DerivativeLiabilityMember 2025-08-26 2025-08-27 0001626644 ODYY:DerivativeLiabilityMember 2025-10-30 2025-10-31 0001626644 ODYY:DerivativeLiabilityMember 2025-11-12 2025-11-13 0001626644 ODYY:DerivativeLiabilityMember 2025-12-30 2025-12-31 0001626644 srt:MinimumMember ODYY:DerivativeLiabilityMember 2025-08-01 2026-01-31 0001626644 srt:MaximumMember ODYY:DerivativeLiabilityMember 2025-08-01 2026-01-31 0001626644 ODYY:DerivativeLiabilityMember 2025-08-01 2026-01-31 0001626644 ODYY:DerivativeLiabilityMember 2025-08-27 0001626644 ODYY:DerivativeLiabilityMember 2025-10-31 0001626644 ODYY:DerivativeLiabilityMember 2025-11-13 0001626644 ODYY:DerivativeLiabilityMember 2025-12-31 0001626644 ODYY:IntellectualPropertyRelatedToMedicalDeviceMember 2026-01-31 0001626644 ODYY:LGHInvestmentsLLCMember 2025-10-05 2025-10-06 0001626644 ODYY:LGHInvestmentsLLCMember ODYY:ConvertiblePromissoryNoteMember ODYY:SecuritiesPurchaseAgreementMember 2026-01-31 0001626644 ODYY:AccreditedInvestorMember ODYY:PromissoryNoteMember 2024-08-14 0001626644 ODYY:AccreditedInvestorMember ODYY:PromissoryNoteMember 2024-08-21 2024-08-22 0001626644 ODYY:AccreditedInvestorMember ODYY:PromissoryNoteMember 2024-08-07 2024-08-14 0001626644 ODYY:AccreditedInvestorMember ODYY:PromissoryNoteMember 2026-01-31 0001626644 ODYY:AccreditedInvestorMember ODYY:PromissoryNoteMember 2025-10-03 0001626644 ODYY:AccreditedInvestorMember ODYY:PromissoryNoteMember 2025-10-02 2025-10-03 0001626644 ODYY:AccreditedInvestorMember ODYY:PromissoryNoteMember ODYY:PeterDArrudaMember 2026-01-31 0001626644 ODYY:AccreditedInvestorMember ODYY:JonathanLutzMember 2024-02-13 0001626644 ODYY:AccreditedInvestorMember ODYY:JonathanLutzMember 2024-06-01 2024-06-30 0001626644 ODYY:AccreditedInvestorMember ODYY:JonathanLutzMember 2025-08-01 2026-01-31 0001626644 ODYY:AccreditedInvestorMember ODYY:JonathanLutzMember 2026-01-31 0001626644 ODYY:SPA2022Member 2025-08-28 2025-08-29 0001626644 ODYY:SPA2022Member 2025-10-08 2025-10-09 0001626644 ODYY:SPA2022Member 2026-01-31 0001626644 ODYY:SPA2025Member 2025-08-27 0001626644 ODYY:SPA2025Member 2025-08-26 2025-08-27 0001626644 ODYY:SPA2025Member 2025-10-31 0001626644 ODYY:SPA2025Member 2025-08-01 2025-10-31 0001626644 ODYY:SPA2025Member 2026-01-31 0001626644 ODYY:SPA2025Member 2025-11-01 2026-01-31 0001626644 ODYY:SPA2025Member 2025-08-01 2026-01-31 0001626644 2025-11-12 2025-11-13 0001626644 ODYY:MastHillMaintenanceAgreementMember 2025-11-13 0001626644 ODYY:MastHillConvertibleNoteMember 2025-11-13 0001626644 ODYY:MastHillConvertibleNoteMember 2025-11-12 2025-11-13 0001626644 ODYY:MastHillConvertibleNoteMember 2026-01-31 0001626644 ODYY:MastHillConvertibleNoteMember 2025-11-01 2026-01-31 0001626644 ODYY:MastHillConvertibleNoteMember 2025-08-01 2026-01-31 0001626644 ODYY:MastHillConvertibleNoteMember 2026-01-31 0001626644 ODYY:MastHillMasterSPANoteMember 2025-11-12 2025-11-13 0001626644 ODYY:MastHillMasterSPANoteMember 2025-11-13 0001626644 ODYY:MastHillSecuritiesPurchaseAgreementMember 2025-11-12 2025-11-13 0001626644 ODYY:TrancheNov2025Member ODYY:MastHillMasterSPANoteMember 2025-11-13 0001626644 ODYY:MastHillMasterSPANoteMember 2025-11-12 2025-11-13 0001626644 ODYY:TrancheNov2025Member ODYY:MastHillMasterSPANoteMember 2025-11-12 2025-11-13 0001626644 ODYY:TrancheNov2025Member ODYY:MastHillMasterSPANoteMember 2026-01-31 0001626644 ODYY:TrancheNov2025Member ODYY:MastHillMasterSPANoteMember 2025-11-01 2026-01-31 0001626644 ODYY:TrancheNov2025Member ODYY:MastHillMasterSPANoteMember 2025-08-01 2026-01-31 0001626644 ODYY:TrancheDec2025Member ODYY:MastHillMasterSPANoteMember 2025-12-31 0001626644 ODYY:TrancheDec2025Member ODYY:MastHillMasterSPANoteMember 2025-12-30 2025-12-31 0001626644 ODYY:TrancheDec2025Member ODYY:MastHillMasterSPANoteMember 2026-01-31 0001626644 ODYY:TrancheDec2025Member ODYY:MastHillMasterSPANoteMember 2025-11-01 2026-01-31 0001626644 ODYY:TrancheDec2025Member ODYY:MastHillMasterSPANoteMember 2025-08-01 2026-01-31 0001626644 ODYY:DirectorsAndOfficersMember 2026-01-31 0001626644 ODYY:DirectorsAndOfficersMember 2026-01-30 2026-01-31 0001626644 ODYY:NotesPayableMember 2026-01-31 0001626644 ODYY:NotesPayableMember 2025-07-31 0001626644 us-gaap:ConvertibleNotesPayableMember 2026-01-31 0001626644 us-gaap:ConvertibleNotesPayableMember 2025-07-31 0001626644 ODYY:Plan2021Member 2026-01-31 0001626644 us-gaap:WarrantMember 2025-07-31 0001626644 us-gaap:WarrantMember 2025-08-01 2026-01-31 0001626644 us-gaap:WarrantMember 2026-01-31 0001626644 ODYY:ConversionOfLGHInvestmentsLLCMember 2025-10-05 2025-10-06 0001626644 ODYY:ConversionOfLGHInvestmentsLLCMember 2025-08-01 2026-01-31 0001626644 us-gaap:StockOptionMember 2025-11-01 2026-01-31 0001626644 us-gaap:StockOptionMember 2024-11-01 2025-01-31 0001626644 us-gaap:StockOptionMember 2025-08-01 2026-01-31 0001626644 us-gaap:StockOptionMember 2024-08-01 2025-01-31 0001626644 ODYY:ConvertibleNotesMember 2025-11-01 2026-01-31 0001626644 ODYY:ConvertibleNotesMember 2024-11-01 2025-01-31 0001626644 ODYY:ConvertibleNotesMember 2025-08-01 2026-01-31 0001626644 ODYY:ConvertibleNotesMember 2024-08-01 2025-01-31 0001626644 us-gaap:WarrantMember 2025-11-01 2026-01-31 0001626644 us-gaap:WarrantMember 2024-11-01 2025-01-31 0001626644 us-gaap:WarrantMember 2025-08-01 2026-01-31 0001626644 us-gaap:WarrantMember 2024-08-01 2025-01-31 0001626644 srt:ChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2026-01-31 0001626644 srt:ChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2025-07-31 0001626644 srt:ChiefFinancialOfficerMember us-gaap:RelatedPartyMember 2026-01-31 0001626644 srt:ChiefFinancialOfficerMember us-gaap:RelatedPartyMember 2025-07-31 0001626644 us-gaap:RelatedPartyMember 2026-01-31 0001626644 us-gaap:RelatedPartyMember 2025-07-31 0001626644 srt:ChiefExecutiveOfficerMember 2026-01-31 0001626644 srt:ChiefExecutiveOfficerMember 2025-07-31 0001626644 srt:ChiefFinancialOfficerMember 2026-01-31 0001626644 srt:ChiefFinancialOfficerMember 2025-07-31 0001626644 ODYY:Director2Member ODYY:ThePromissoryNotesMember 2026-01-31 iso4217:USD shares iso4217:USD shares pure ODYY:Integer false --07-31 2026 Q2 0001626644

P2Y4M17D

10-Q true 2026-01-31 false 000-56196 Odyssey Health, Inc. NV 47-1022125 2300 West Sahara Avenue Suite 800 - #4012 Las Vegas NV 89102 702 780-6559 Common Stock ($0.001 par value) ODYY Yes Yes Non-accelerated Filer true false false 99853763

616327

19084

104977

30639

721304

49723

721304

49723

1620079

1615357

1857004

1858443

509348

421440

1125026

100000 100000

3122747

512

2169500

1884155

3936166

11317123

7004421

0.001

100000000

0.001

500000000

99853763

96709763

99854

96710

56135234

55694429

-66830907

-62745837

-10595819

-6954698

721304

49723

181942

156593

485132

736020

-181942

-156593

-485132

-736020

-370698

412429

63431

507765

132217

2572655 -0 3080023 -0

-424348

-1929

-10249

-102

-10221

-97

-3601623

-220126

-4085070

-1239032

-0.03

-0.00

-0.04

-0.01

-0.03

-0.00

-0.04

-0.01

107853763

104709763

106945198

104709763

107853763

104709763

106945198

104709763

96709763

96710

55694429

-62745837

-6954698

1144000

1144

81224

82368

2000000

2000

142000

144000

56589

-483447

99853763

99854

55974242

-63229284

-7155188

160992

-3601623

99853763

99854

56135234

-66830907

-10595819

96709763

96710

55572687

-61003146

-5333749

60487

13343

-1018906

96709763

96710

55646517

-62022052

-6278825

36131

-220126

96709763

96710

55682648

-62242178

-6462820

-4085070

-1239032

96618

0 22625 3080023 0

-1929

-0

328791

31831

-0

-370698

1750

74338

69235

4722

195538

-1439

197137

175375

98628

-568257

-295192

1165500

300000

1165500

300000

597243

4808

19084

2379

616327

7187

3598

1758

144000 0 80618 0 217581 13343 2085771 0 6849 0 1184943 0

Note 1. Basis of Presentation and Nature of Operations Basis of Presentation The accompanying condensed consolidated financial information of Odyssey Health, Inc. and our wholly-owned subsidiaries Odyssey Medical Devices, Inc. and Odyssey Group International Australia, Pty Ltd is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany balances and transactions have been eliminated. Such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the condensed consolidated financial position, results of operations and cash flows for the interim periods. The consolidated financial information as of July 31, 2025, is derived from our Annual Report on Form 10-K for the year ended July 31, 2025. The condensed consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2025 Annual Report on Form 10-K filed with the SEC on October 29, 2025. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year. Significant Accounting Policies Other than as described below, our significant accounting policies have not changed during the six months ended January 31, 2026 from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2025. Segment Reporting We operate as one reportable segment under ASC 280, Segment Reporting. The Chief Operating Decision Maker, reviews and evaluates financial information and allocates resources on a consolidated basis when making operating decisions and assessing performance. Accounting for Derivative Liabilities We have derivative liabilities related to outstanding debt with a variable conversion features. We accounted for the fair value of the derivative liability utilizing a Black-Scholes pricing model upon inception and mark it to fair value using the Black-Scholes pricing model as of the end of each reporting period with the change in fair value being accounted for in the Condensed Consolidated Statements of Operations and Comprehensive Loss in the period incurred. See also Notes 4 and 5. Reclassification We have reclassified, combined or separately disclosed certain amounts in the prior years’ condensed consolidated financial statements and accompanying footnotes to conform with the current year’s presentation. These changes consisted of separating Accounts payable and accrued wages, officers from Accounts payable and Accrued wages within the January 31, 2025 condensed consolidated statement of cash flows and Stock-based compensation was reclassified in the prior period financial statements to be a component of General and administrative expense in order to conform with the current period presentation. There was no effect on the reported Net loss for the periods. Nature of Operations Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have superior clinical utility and serve an unmet medical need. Our business model is to develop or acquire medical-related products, engage third parties to help develop such products, complete clinical trials, and manufacture products according to U. S. Food and Drug Administration (“FDA”) regulations. We have two different technologies in development; the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device. We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products, and we will apply for trademarks and patents once we have developed proprietary products. We are not currently selling or marketing any products, as our products are in development, and FDA clearance or approval to market our products will be required to sell in the United States. In addition, we would require additional European Union or country specific clearance or approvals to sell internationally. Going Concern We did not recognize any revenues for the year ended July 31, 2025, and we had an accumulated deficit of $66,830,907 as of January 31, 2026. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations. As of January 31, 2026, we had current liabilities of $11,317,123, current assets of $721,304, and a working capital deficit of $10,595,819. At January 31, 2026, based on current projections and anticipated funding sources, we believe we have sufficient working capital to meet our operating expenses through the end of fiscal 2026, subject to the risks and uncertainties described herein. The operating deficit and negative working capital at January 31, 2026, indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty. We are continually adjusting our business plan to reflect our current liquidity expectations. If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.

Basis of Presentation The accompanying condensed consolidated financial information of Odyssey Health, Inc. and our wholly-owned subsidiaries Odyssey Medical Devices, Inc. and Odyssey Group International Australia, Pty Ltd is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany balances and transactions have been eliminated. Such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the condensed consolidated financial position, results of operations and cash flows for the interim periods. The consolidated financial information as of July 31, 2025, is derived from our Annual Report on Form 10-K for the year ended July 31, 2025. The condensed consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2025 Annual Report on Form 10-K filed with the SEC on October 29, 2025. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.

Significant Accounting Policies Other than as described below, our significant accounting policies have not changed during the six months ended January 31, 2026 from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2025.

Segment Reporting We operate as one reportable segment under ASC 280, Segment Reporting. The Chief Operating Decision Maker, reviews and evaluates financial information and allocates resources on a consolidated basis when making operating decisions and assessing performance.

Accounting for Derivative Liabilities We have derivative liabilities related to outstanding debt with a variable conversion features. We accounted for the fair value of the derivative liability utilizing a Black-Scholes pricing model upon inception and mark it to fair value using the Black-Scholes pricing model as of the end of each reporting period with the change in fair value being accounted for in the Condensed Consolidated Statements of Operations and Comprehensive Loss in the period incurred. See also Notes 4 and 5.

Reclassification We have reclassified, combined or separately disclosed certain amounts in the prior years’ condensed consolidated financial statements and accompanying footnotes to conform with the current year’s presentation. These changes consisted of separating Accounts payable and accrued wages, officers from Accounts payable and Accrued wages within the January 31, 2025 condensed consolidated statement of cash flows and Stock-based compensation was reclassified in the prior period financial statements to be a component of General and administrative expense in order to conform with the current period presentation. There was no effect on the reported Net loss for the periods.

Nature of Operations Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have superior clinical utility and serve an unmet medical need. Our business model is to develop or acquire medical-related products, engage third parties to help develop such products, complete clinical trials, and manufacture products according to U. S. Food and Drug Administration (“FDA”) regulations. We have two different technologies in development; the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device. We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products, and we will apply for trademarks and patents once we have developed proprietary products. We are not currently selling or marketing any products, as our products are in development, and FDA clearance or approval to market our products will be required to sell in the United States. In addition, we would require additional European Union or country specific clearance or approvals to sell internationally.

Going Concern We did not recognize any revenues for the year ended July 31, 2025, and we had an accumulated deficit of $66,830,907 as of January 31, 2026. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations. As of January 31, 2026, we had current liabilities of $11,317,123, current assets of $721,304, and a working capital deficit of $10,595,819. At January 31, 2026, based on current projections and anticipated funding sources, we believe we have sufficient working capital to meet our operating expenses through the end of fiscal 2026, subject to the risks and uncertainties described herein. The operating deficit and negative working capital at January 31, 2026, indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty. We are continually adjusting our business plan to reflect our current liquidity expectations. If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.

-66830907

11317123

721304

-10595819

Note 2. New Accounting Pronouncements ASU 2023-09 In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments will be effective for the Company’s July 31, 2026 fiscal year end financial statements. The amendments should be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating this ASU to determine its impact on our disclosures and do not expect the amendments to have a material effect on our financial statements. ASU 2024-03 In November 2024, the FASB issued ASU 2024-03, Comprehensive Income (Topic 220): Disaggregation of Income Statement Expense, related to the disaggregation of certain income statement expenses. The amendments in this update require public entities to disclose incremental information related to purchases of inventory, team member compensation and depreciation, which will provide investors the ability to better understand entity expenses and make their own judgements about entity performance. The amendments in this update are effective for fiscal years beginning after December 15, 2026. We plan to adopt this pronouncement and make the necessary updates to our disclosures for the year ending July 31, 2027, and, aside from these disclosure changes, we do not expect the amendments to have a material effect on our financial statements.

Note 3. Commitments and Contingencies Master Technology and Sub-License Agreement On October 14, 2025, we entered into a Master Technology and Sub-license Agreement (the “Agreement”) with NeuRX Health, Inc. (“NeuRX”). Pursuant to the Agreement, we entered into a sub-licensing agreement for exclusive, worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities. The Agreement, anticipated to close in the first quarter of 2026, is subject to finalization of certain material terms and closing conditions, and there can be no assurance that the transaction will close on the anticipated timeline or at all. Terms include worldwide license to the technology, a royalty agreement, sublicense agreement and material transfer agreement. Cash consideration will be paid to NeuRX every time we make a draw on our Mast Hill equity line of credit. The amount to be paid to NeuRX will equal 30% of the net cash proceeds received from draws under the equity line of credit calculated after satisfaction of payment obligations to certain debt holders throughout the life of the equity line of credit. Upon closing of the Agreement, we will be responsible for all manufacturing, distribution, marketing and sales of BreastCheck®.

Note 4. Fair Value The fair value of financial assets and liabilities are determined utilizing a three-level framework as follows: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities. Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although we believe our valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. We did not have any transfers of assets or liabilities measured at fair value on a recurring basis to or from Level 1, Level 2, or Level 3 during the six months ended January 31, 2026, or the year ended July 31, 2025. No changes were made to our valuation techniques during the quarter ended January 31, 2026. We did not have any financial instruments carried at fair value at July 31, 2025. Financial instruments carried at fair value at January 31, 2026 included the following: <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zS9XCpchwkZ9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value (Details - Financial instruments carried at fair value)"> <tr style="vertical-align: bottom"> <td>Schedule of fair value of financial instruments</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: left">Derivative liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_d0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zdVZGBO11oW4" style="width: 13%; text-align: right" title="Equity method investment">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_d0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_fKDEp_zAf2dJiaemJi" style="width: 13%; text-align: right" title="Equity method investment">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_d0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zU2HsJMPLk2c" style="width: 13%; text-align: right" title="Equity method investment">3,936,166</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_c20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_z15QWICzV384" style="width: 13%; text-align: right" title="Equity method investment">3,936,166</td><td style="width: 1%; text-align: left"> </td></tr> </table> Derivative Liabilities Derivative liabilities relates to the variable conversion feature embedded in our August 27, 2025 Securities Purchase Agreement, our November 13, 2025 Convertible Promissory Note and Maintenance Agreement and our November 13, 2025 Securities Purchase Agreement with Mast Hill Fund L.P. and our December 31, 2025 Second Tranche related to the November 13, 2025 Securities Purchase Agreement. See Note 5 for additional information. The fair value of our derivative liabilities as of August 27, 2025 (inception), October 31, 2025, November 13, 2025 (inception), December 31, 2025 (inception), and January 31, 2026, was determined using the Black-Scholes pricing model utilizing the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_ztR3149THRWa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value (Details - Assumptions)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August 27, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">November 13, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 25%; text-align: left">Expected stock price volatility</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250826__20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_ztp5aRWEaJni" title="Expected stock price volatility">228.72%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251030__20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zFl1NJmnP9E5" title="Expected stock price volatility">251.16%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251112__20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zNaXCbDDpdt9" title="Expected stock price volatility">236.31%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251230__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_znNn4RDMcCQf" title="Expected stock price volatility">234.40%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MinimumMember_zaYMUMCrDvE3" title="Expected stock price volatility">243.00%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MaximumMember_zGimlIGtYuM" title="Expected stock price volatility">269.04%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250826__20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zKsLDyeY51d9" title="Risk free interest rate">3.83%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251030__20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zCi6UtgUdfS6" title="Risk free interest rate">3.75%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251112__20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSoXHxGaYNB" title="Risk free interest rate">3.68%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251230__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_z0i8PcPXrzlk" title="Risk free interest rate">3.48%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MinimumMember_z0Ykz0u8nWPb">3.47%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MaximumMember_zGG00zcUyho1">3.61%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250826__20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zmMaCXG2ihD7" title="Expected life of options (years)">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251030__20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zLuUIzrExjZj" title="Expected life of options (years)">0.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251112__20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zstiMHcJAKr9" title="Expected life of options (years)">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251230__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_z5UVKUe7X8li" title="Expected life of options (years)">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MinimumMember_zRFVjKK353nd" title="Expected life of options (years)">0.57 – <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MaximumMember_zF39gg4UWA93" title="Expected life of options (years)">0.92 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250826__20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zbufx1gRKaa5" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251030__20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zdgiXuWO35T3" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251112__20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zqjTor7tHugg" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251230__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zrXcBxpZJRI9" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_z0vXtR5DWgg2" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zVH1cUQtyXC" title="Exercise price">0.024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zV0moAxMkPk1" title="Exercise price">0.058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zZsFn3hV5xVa" title="Exercise price">0.058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zDbVdxWiqNf7" title="Exercise price">0.026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSxGSowUW9Af" title="Exercise price">0.050</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.074</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.071</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.072</td><td style="text-align: left"> </td></tr> </table> Our derivative liabilities were as follows: <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zitl8uF5cel8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value (Details - Derivative liabilities)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 20pt">Schedule of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended January 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Beginning balance at July 31, 2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_d0_c20250801__20251031_zOemijGYChD4" style="text-align: right" title="Derivative liabilities at beginning">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 83%; text-indent: 20pt"> Additional derivative liability recognized</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--AdditionalDerivativeLiabilityRecognized_c20250801__20251031_zzaIUNoG2eUg" style="width: 13%; text-align: right" title="Additional derivative liability recognized">647,574</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-indent: 20pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20250801__20251031_zBFCX5TRc8Ed" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on measurement">(422,419</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_c20251101__20260131_z6DoqLn2yW1e" style="text-align: right" title="Derivative liabilities at beginning">225,155</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: 20pt">Additional derivative liabilities recognized</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--AdditionalDerivativeLiabilityRecognized_c20251101__20260131_zRirrCIAIv2e" style="text-align: right" title="November 13, 2025">3,286,663</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: 20pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeGainLossOnDerivativeNet_c20251101__20260131_zhyGwZI7r15k" style="border-bottom: Black 1pt solid; text-align: right" title="November 13, 2025 SPA Tranche">424,348</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Ending balance at January 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iE_c20251101__20260131_zdAezf2R3yj" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liabilities at ending">3,936,166</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> See also Note 5. Fair Value of Current Assets and Liabilities The carrying values of Cash, Accounts payable and accrued wages, Accounts payable and accrued wages - officers, and Notes payable approximate their fair value due to their short maturities. Contingent Liability At January 31, 2026 and July 31, 2025, we had contingent consideration related to the acquisition of intellectual property, know-how and patents for an anti-choking, life-saving medical device in fiscal 2019. According to the agreement, we will make a one-time cash payment totaling $<span id="xdx_900_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20260131__us-gaap--ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis__custom--IntellectualPropertyRelatedToMedicalDeviceMember_zpc5Kmnc5Rvc" title="Contingent consideration">250,000 upon FDA clearance of the device. The fair value of the contingent consideration is reviewed quarterly and determined based on the current status of the project (Level 3). We determined the value was zero at both periods since it is not yet probable that we will file for FDA clearance.

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--FairValueByBalanceSheetGroupingTextBlock_zS9XCpchwkZ9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value (Details - Financial instruments carried at fair value)"> <tr style="vertical-align: bottom"> <td>Schedule of fair value of financial instruments</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: left">Derivative liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_d0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zdVZGBO11oW4" style="width: 13%; text-align: right" title="Equity method investment">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_d0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_fKDEp_zAf2dJiaemJi" style="width: 13%; text-align: right" title="Equity method investment">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_d0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zU2HsJMPLk2c" style="width: 13%; text-align: right" title="Equity method investment">3,936,166</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_c20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_z15QWICzV384" style="width: 13%; text-align: right" title="Equity method investment">3,936,166</td><td style="width: 1%; text-align: left"> </td></tr> </table>

3936166

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_ztR3149THRWa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value (Details - Assumptions)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">August 27, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">November 13, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 25%; text-align: left">Expected stock price volatility</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250826__20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_ztp5aRWEaJni" title="Expected stock price volatility">228.72%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251030__20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zFl1NJmnP9E5" title="Expected stock price volatility">251.16%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251112__20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zNaXCbDDpdt9" title="Expected stock price volatility">236.31%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251230__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_znNn4RDMcCQf" title="Expected stock price volatility">234.40%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MinimumMember_zaYMUMCrDvE3" title="Expected stock price volatility">243.00%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MaximumMember_zGimlIGtYuM" title="Expected stock price volatility">269.04%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250826__20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zKsLDyeY51d9" title="Risk free interest rate">3.83%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251030__20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zCi6UtgUdfS6" title="Risk free interest rate">3.75%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251112__20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSoXHxGaYNB" title="Risk free interest rate">3.68%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251230__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_z0i8PcPXrzlk" title="Risk free interest rate">3.48%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MinimumMember_z0Ykz0u8nWPb">3.47%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MaximumMember_zGG00zcUyho1">3.61%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250826__20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zmMaCXG2ihD7" title="Expected life of options (years)">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251030__20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zLuUIzrExjZj" title="Expected life of options (years)">0.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251112__20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zstiMHcJAKr9" title="Expected life of options (years)">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251230__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_z5UVKUe7X8li" title="Expected life of options (years)">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MinimumMember_zRFVjKK353nd" title="Expected life of options (years)">0.57 – <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember__srt--RangeAxis__srt--MaximumMember_zF39gg4UWA93" title="Expected life of options (years)">0.92 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250826__20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zbufx1gRKaa5" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251030__20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zdgiXuWO35T3" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251112__20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zqjTor7tHugg" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251230__20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zrXcBxpZJRI9" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250801__20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_z0vXtR5DWgg2" title="Expected dividend yield">0.00%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250827__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zVH1cUQtyXC" title="Exercise price">0.024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251031__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zV0moAxMkPk1" title="Exercise price">0.058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251113__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zZsFn3hV5xVa" title="Exercise price">0.058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zDbVdxWiqNf7" title="Exercise price">0.026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260131__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityMember_zSxGSowUW9Af" title="Exercise price">0.050</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.074</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.071</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.072</td><td style="text-align: left"> </td></tr> </table>

2.2872

2.5116

2.3631

2.3440

2.4300

2.6904

0.0383

0.0375

0.0368

0.0348

0.0347

0.0361

P1Y

P0Y9M29D

P1Y

P0Y6M25D

P0Y11M1D

0.0000

0.024

0.058

0.026

0.050

0.082

0.074

0.071

0.033

0.072

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zitl8uF5cel8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value (Details - Derivative liabilities)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 20pt">Schedule of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended January 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Beginning balance at July 31, 2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_d0_c20250801__20251031_zOemijGYChD4" style="text-align: right" title="Derivative liabilities at beginning">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 83%; text-indent: 20pt"> Additional derivative liability recognized</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--AdditionalDerivativeLiabilityRecognized_c20250801__20251031_zzaIUNoG2eUg" style="width: 13%; text-align: right" title="Additional derivative liability recognized">647,574</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-indent: 20pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20250801__20251031_zBFCX5TRc8Ed" style="border-bottom: Black 1pt solid; text-align: right" title="Gain on measurement">(422,419</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at October 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_c20251101__20260131_z6DoqLn2yW1e" style="text-align: right" title="Derivative liabilities at beginning">225,155</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: 20pt">Additional derivative liabilities recognized</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--AdditionalDerivativeLiabilityRecognized_c20251101__20260131_zRirrCIAIv2e" style="text-align: right" title="November 13, 2025">3,286,663</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: 20pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeGainLossOnDerivativeNet_c20251101__20260131_zhyGwZI7r15k" style="border-bottom: Black 1pt solid; text-align: right" title="November 13, 2025 SPA Tranche">424,348</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Ending balance at January 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iE_c20251101__20260131_zdAezf2R3yj" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liabilities at ending">3,936,166</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

647574

422419

225155

3286663

424348

3936166

250000

Note 5. Debt Our debt instruments consist of Convertible notes payable, officers and directors, Notes payable, and Convertible notes payable. All of our debt instruments are unsecured. Key terms of our various debt instruments are as follows: LGH Investments, LLC On September 15, 2025, and effective July 31, 2025, we entered into Amendment No. 10 to the Convertible Promissory Note pursuant to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”) (the “Note”) which extended the maturity date of the Note to January 31, 2026. On October 6, 2025, LGH converted $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20251005__20251006__srt--CounterpartyNameAxis__custom--LGHInvestmentsLLCMember_zJsCB1NB321c" title="Debt converted, amount converted">144,000 of their outstanding Note into 2,000,000 shares of our common stock at $0.072 per share. On January 31, 2026, we entered into Amendment No. 11 to the Convertible Promissory Note to extend the maturity date to April 30, 2026. At January 31, 2026, we had $<span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20260131__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--LGHInvestmentsLLCMember_zQDYJkiZI10i" title="Convertible note payable balance">891,000 of principal and $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20260131__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--LGHInvestmentsLLCMember_zpBcTPD90gUl" title="Interest payable">294,723 of accrued interest outstanding pursuant to the Note. Accredited Investor Promissory Notes $300,000 Promissory Note On August 14, 2024, we entered into a $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20240814__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z9B8OsVaoiCj" title="Notes payable">300,000 promissory note (the “Note”) with Peter D’Arruda, an accredited investor. The $<span id="xdx_90C_eus-gaap--ProceedsFromNotesPayable_c20240821__20240822__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zFBVEfKstiPh" title="Proceeds from stock received">300,000 was received on August 22, 2024. The Note has a one-year maturity, becoming due on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20240807__20240814__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z362LXRi4K3l" title="Maturity date">August 22, 2025, and bears interest at the rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240814__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_ztXZgMNRyDr5" title="Interest rate">18% per annum. In addition, we issued the investor an immediately exercisable warrant to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240814__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zS1lNR16aCX9" title="Warrant to purchase">300,000 shares of our common stock at $0.10 per share that expires <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240807__20240814__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zGwirM9EJW57" title="Expires date">August 14, 2029, with a fair value of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20240814__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zSTyxxSX2GF" title="Warrants issued, fair value">13,343. On August 14, 2025, this Note was amended to extend the maturity date to January 31, 2026. On Feb 2, 2026 with an effective date of January 31, 2026, this Note was amended to extend the maturity date to January 31, 2027. At January 31, 2026, $<span id="xdx_90B_eus-gaap--NotesPayable_iI_c20260131__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zQ47lVa8Ctr7" title="Notes payable">300,000 in principal and $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260131__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zxrVcVTvw4Jl" title="Accrued interest">79,149 in accrued interest remained outstanding. $100,000 Promissory Note On October 3, 2025, we entered into a $<span id="xdx_90A_eus-gaap--NotesPayable_iI_c20251003__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zZ5HgaCHWNEk" title="Notes payable">100,000 promissory note with an effective date of October 1, 2025, with Peter D’Arruda, an accredited investor. The $<span id="xdx_900_eus-gaap--ProceedsFromNotesPayable_c20251002__20251003__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zXeL1qz6HTli" title="Proceeds from stock received">100,000 was received October 3, 2025. The note has a one-year maturity, becoming due on <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20251002__20251003__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zkfRRCjIVfS3" title="Maturity date">September 30, 2026, and bears interest at the rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20251003__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zAgafqB46MYe" title="Interest rate">18% per annum. In addition, we issued the investor an immediately exercisable warrant to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20251003__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zDzaNVYl1uYe" title="Warrant to purchase">100,000 shares of our common stock at $<span id="xdx_909_eus-gaap--SharePrice_iI_c20251003__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zvPRKLiz1d08" title="Share price">0.10 per share that expires <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20251002__20251003__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zX5XgHsCI6Y2" title="Expires date">September 30, 2030. At January 31, 2026, $<span id="xdx_90D_eus-gaap--NotesPayable_iI_c20260131__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionAxis__custom--PeterDArrudaMember_zsTpQ18Lnkj1" title="Notes payable">100,000 in principal and $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260131__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionAxis__custom--PeterDArrudaMember_z0FkUfdtQPkl" title="Accrued interest">6,067 in accrued interest remained outstanding. $50,000 Promissory Note On February 13, 2024, we entered into a six-month promissory note for $<span id="xdx_903_eus-gaap--NotesPayable_iI_c20240213__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--JonathanLutzMember_zPcRPEqB29Fa" title="Notes payable">50,000, with Jonathan Lutz, an accredited investor, with an interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240213__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--JonathanLutzMember_zWbMBtPsZTe1" title="Interest rate">10% per annum, due August 11, 2024, and convertible into 20,000 shares of Oragenics, Inc. common stock currently held by us at the investor’s option. In June 2024, this note was amended to provide for settlement of the note by issuing the accredited investor <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240601__20240630__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--JonathanLutzMember_zlVksd52ePIk" title="Number of shares issued">30,000 shares of Oragenics common stock when the Oragenics preferred stock held by us is converted into Oragenics common stock. On January 31, 2026, this note was amended to extend the maturity date to <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20250801__20260131__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--JonathanLutzMember_zm9Jx0qWHEOi" title="Maturity date">January 31, 2027. At January 31, 2026, $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20260131__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--JonathanLutzMember_zm6tofPOU6U8" title="Notes payable">50,000 in principal and $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260131__srt--CounterpartyNameAxis__custom--AccreditedInvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--JonathanLutzMember_zp9NOPzjhHR5" title="Accrued interest">9,841 in accrued interest remained outstanding. Mast Hill Fund L.P. Our unsecured debt instruments with Mast Hill have priority over our other unsecured debt in payment and performance. Our debt instruments with Mast Hill also have terms that restrict (a) distributions on our common stock, (b) stock repurchases, (c) the sale of any significant portion of our assets, and (d) certain advances and loans (all as defined within the Mast Hill debt agreements) without Mast Hill’s written consent. Details of our debt instruments with Mast Hill are as follows: July 29, 2025 Common Stock Purchase Agreement Pursuant to an Equity Purchase Agreement (the “Agreement”) dated July 29, 2025, we have the right, but not the obligation, to deliver Put Notices to Mast Hill Fund L.P. (“Mast Hill”) to purchase Put Shares of our common stock totaling up to $25.0 million. Each Put Notice will be (i) in a minimum amount not less than $5,000 and (ii) in a maximum amount up to the lesser of (a) $500,000 or (b) 20% of the Average Daily Trading Value. The lesser of (a) or (b) is referred to as the Maximum Daily Put Amount. We may, at our option, specify a minimum share price with respect to our common stock (the “Minimum Price”) in a Put Notice at the time that the Put Notice is delivered to Mast Hill. To date, no Put Notices were delivered to Mast Hill under the Agreement. December 13, 2022 Securities Purchase Agreement Pursuant to the Securities Purchase Agreement with Mast Hill dated December 13, 2022 (the “2022 SPA”), on August 29, 2025, Mast Hill converted $<span id="xdx_904_ecustom--DebtConversionConvertedInterestAmount1_c20250828__20250829__us-gaap--SecuritiesFinancingTransactionAxis__custom--SPA2022Member_zrp5DWe6uuN1" title="Debt converted, interest converted">80,618 of interest and $1,750 in fees for a total of $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20250828__20250829__us-gaap--SecuritiesFinancingTransactionAxis__custom--SPA2022Member_zF9ggnt1QEQ6" title="Debt converted, amount converted">82,368 into <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250828__20250829__us-gaap--SecuritiesFinancingTransactionAxis__custom--SPA2022Member_zKQs4KvN3Ac4" title="Debt converted, shares issued">1,144,000 shares of our common stock at a price of $0.072 per share. On October 9, 2025, we entered into Amendment No. 6 to the 2022 SPA, extending the maturity date for the full amount outstanding to April 30, 2026. At January 31, 2026, there was $499,667 of principal, $21,231 of accrued interest, and warrants exercisable for 14,666,667 shares of our common stock outstanding pursuant to the 2022 SPA. August 27, 2025 Securities Purchase Agreement On August 27, 2025, we entered into a Securities Purchase Agreement (the “2025 SPA”) with Mast Hill Fund L.P. (“Mast Hill”). Pursuant to the 2025 SPA, we sold Mast Hill (i) a $220,000 face value, one-year, 10% per annum Promissory Note (the “Note”) convertible into shares of our common stock at 85% of the lowest volume-weighted average price of our common stock during the ten trading days immediately preceding the respective conversion date, and (ii) a five-year warrant that is immediately exercisable entitling Mast Hill to acquire <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250827__us-gaap--SecuritiesFinancingTransactionAxis__custom--SPA2025Member_zRdtfEc5jbjj" title="Warrants issued">1,000,000 shares of our common stock at $0.10 per share. If the market price of our common stock is greater than the exercise price, Mast Hill may elect to receive warrant shares pursuant to a cashless exercise. Any principal or interest on this Note which is not paid when due shall bear interest at the rate of the lesser of (i) 16% per annum or (ii) the maximum rate permitted by law, from the due date thereof until the same is paid. Net proceeds after original discount of $22,000, fees and expenses was $190,500. Due to the variability of the conversion feature, it is valued separately from the underlying debt as an embedded conversion feature, which is a derivative liability. Using the Black-Scholes pricing model, we determined the fair value of the derivative liability to be $647,574 at inception. The fair value of the derivative liability in excess of the available face value of the note, net of all discounts from other sources, was recorded as a day one financing cost totaling $507,368. The derivative liability was revalued at October 31, 2025 with an estimated fair value of $225,155. Accordingly, a gain on change in fair value of derivative liability in the amount of $422,419 was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended October 31, 2025. The derivative liability was revalued at January 31, 2026, with an estimated fair value of $223,173. Accordingly, a gain on change in fair value of derivative liabilities in the amount of $<span id="xdx_903_eus-gaap--UnrealizedGainLossOnDerivatives_c20251101__20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--SPA2025Member_zj4xMh9dNcba" title="Change in fair value of derivative liability">1,982 was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended January 31, 2026, and a gain of $<span id="xdx_90A_eus-gaap--DerivativeGainOnDerivative_c20250801__20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--SPA2025Member_zxVfUjZrwWfi" title="Change in fair value of derivative liability">424,401 was recorded for the six months ended January 31, 2026. See also Note 4. At January 31, 2026, there was $220,000 of principal, $9,403 of accrued interest, and warrants exercisable for 1,000,000 shares of our common stock outstanding pursuant to the 2025 SPA. November 13, 2025 Convertible Promissory Note and Maintenance Agreement To consummate a separate November 13, 2025 Securities Purchase Agreement with Mast Hill, we entered into a maintenance agreement and a maintenance note with Mast Hill. The net effect from the maintenance agreement and note was an upfront expense of $330,030, which was recorded as a day one financing cost. The terms of the maintenance agreement and maintenance note are described below. On November 13, 2025, we entered into a Maintenance Agreement with Mast Hill, pursuant to which we agreed to provide certain maintenance and related services for a commercial facility beginning November 13, 2025 and ending on the first business day of February 2034. In exchange, Mast Hill will pay us service fees (the “Fees”) which currently total approximately $<span id="xdx_90A_ecustom--AnnualServicesFees_iI_c20251113__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--MastHillMaintenanceAgreementMember_zy3nDhthSV8k" title="Estimated annual service fees">252,450 per year that is an offset to the principal and interest payable against the outstanding tranches. For financial statement presentation, future Fees receivable under the Maintenance Agreement will be offset against any debt owed to Mast Hill. As of January 31, 2026, $1,842,002 in future Fees receivable was offset against Notes payable. In connection with the Maintenance Agreement, we issued to Mast Hill a convertible promissory note in the amount of $2,262,000 which bears interest at 10% per annum and is due November 13, 2026 (the “Maintenance Note”) in exchange for the Fees to be received as described above. The Maintenance Note plus any accrued but unpaid interest is convertible at any time by Mast Hill into shares of our common stock at a price equal to 85% of the lowest volume weighted average price during the preceding 10 trading days. Due to the variability of the conversion feature, it is valued separately from the underlying debt as an embedded conversion feature, which is a derivative liability. Using the Black-Scholes pricing model, we determined the fair value of the derivative liability to be $2,242,625 at inception. The fair value of the derivative liability in excess of the available face value of the note, net of all discounts from other sources, was recorded as a day one financing cost totaling $2,242,625. The derivative liability was revalued at January 31, 2026 with an estimated fair value of $<span id="xdx_90E_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20260131__us-gaap--LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis__custom--MastHillConvertibleNoteMember_z99FANZNrP22" title="Derivative liability fair value">2,621,970. Accordingly, a loss on change in fair value of derivative liabilities in the amount of $<span id="xdx_901_eus-gaap--UnrealizedGainLossOnDerivatives_c20251101__20260131__us-gaap--LongtermDebtTypeAxis__custom--MastHillConvertibleNoteMember_zW49c1ThIKF5" title="Change in fair value of derivative liability"><span id="xdx_90D_eus-gaap--UnrealizedGainLossOnDerivatives_c20250801__20260131__us-gaap--LongtermDebtTypeAxis__custom--MastHillConvertibleNoteMember_zchUGk1RoAY2" title="Change in fair value of derivative liability">379,345 was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended January 31, 2026. See also Note 4. At January 31, 2026, there was $2,262,000 of principal, $48,339 of accrued interest pursuant to the Maintenance Note. Pursuant to the terms of the Maintenance Note, we will remit any service fees received, less direct costs, to Mast Hill as payment on the Master Note tranches until paid in full or converted. The service fees under the Maintenance Agreement will not exceed the debt incurred under the Maintenance Note. Accordingly, we do not expect to record any revenues in the future under the Maintenance Agreement, as proceeds will only reduce the future Fees receivable, which are netted against Notes payable. November 13, 2025 Mast Hill Securities Purchase Agreement On November 13, 2025, we entered into a Securities Purchase Agreement (the “SPA”) with Mast Hill. Pursuant to the terms of the SPA, we issued a promissory note with a maximum principal amount of up to $25,000,000 in multiple tranches (the “Master SPA Note”). Pursuant to the terms of the SPA, there is an original issue discount (“OID”) of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20251113__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember_zrdV5T8gLPoc" title="Original issue discount">10% on each tranche. Accordingly, the maximum proceeds to us, when considering the 10% OID, is $<span id="xdx_90E_eus-gaap--PaymentsOfDebtExtinguishmentCosts_c20251112__20251113__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillSecuritiesPurchaseAgreementMember_zmStcXZoTeMg" title="Costs and fees">22,250,000 less any related costs and fees. The SPA Note is convertible at any time by Mast Hill into shares of our common stock at 85% of the lowest volume weighted average price during the preceding 10 trading days. With each tranche, we will issue to Mast Hill common stock purchase warrants (“Warrants”) exercisable at $0.001 per share in an amount equal to 20% of the principal amount of the tranche divided by the lowest traded price of our common stock during the 10 trading days preceding each funding date. November 13, 2025 Tranche On November 13, 2025, we entered into the first tranche of the SPA consisting of $<span id="xdx_906_eus-gaap--NotesAndLoansPayable_iI_c20251113__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_zIW5i7lMpxRi" title="Note payable">500,000 principal with an original discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251113__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_zktIxtc8m005">50,000 and legal fees totaling $12,500 for net proceeds to us of $<span id="xdx_907_eus-gaap--ProceedsFromNotesPayable_c20251112__20251113__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_zHa8g9gsbwV5">437,500. In conjunction with this tranche, we issued Warrants to Mast Hill immediately exercisable for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20251113__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_z3Vg4cKf4NBe">1,538,461 shares of our common stock at $0.001 per share. Due to the variability of the conversion feature, it is valued separately from the underlying debt as an embedded conversion feature, which is a derivative liability. Using the Black-Scholes pricing model, we determined the fair value of the derivative liability to be $<span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20251113__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_zbbeSCBOml99">495,717 at inception. The fair value of the derivative liability in excess of the available face value of the note, net of all discounts from other sources, was recorded as a day one financing cost totaling $<span id="xdx_907_eus-gaap--PaymentsOfFinancingCosts_c20251112__20251113__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_zgFReEHVv59c">137,410. The derivative liability was revalued at January 31, 2026 with an estimated fair value of $<span id="xdx_90D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_z7laAlohtzj4">516,745. Accordingly, a loss on change in fair value of derivative liabilities in the amount of $<span id="xdx_90F_eus-gaap--DerivativeLossOnDerivative_c20251101__20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_zWVRfPIOHWG3"><span id="xdx_90E_eus-gaap--DerivativeLossOnDerivative_c20250801__20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_zry2ekVI8Hql">21,028 was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Loss for each of the three and six month periods ended January 31, 2026. See also Note 4. At January 31, 2026, there was $<span id="xdx_90F_eus-gaap--NotesAndLoansPayable_iI_c20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_z2gWc7BAdJfb" title="Note payable">469,580 of principal, $<span id="xdx_906_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_z6jZPUZXfnLe" title="Accrued interest">3,731 of accrued interest, and warrants exercisable for <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheNov2025Member_z0UTNfFzOmdg" title="Warrants outstanding">1,538,461 shares of our common stock outstanding pursuant to the November 13, 2025 tranche. December 31, 2025 Tranche On December 31, 2025, we entered into the second tranche of the SPA consisting of $<span id="xdx_904_eus-gaap--NotesAndLoansPayable_iI_c20251231__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zqq7BwHPfL6c" title="Note payable">500,000 principal with an original discount of $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251231__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zXzYb8FkylDb">50,000 and legal fees totaling $<span id="xdx_905_eus-gaap--PaymentsOfDebtIssuanceCosts_c20251230__20251231__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zjPvrMBrhe5">12,500 for net proceeds to us of $<span id="xdx_905_eus-gaap--ProceedsFromNotesPayable_c20251230__20251231__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zKCxQdvJb03f">437,500. In conjunction with this tranche, we issued Warrants to Mast Hill immediately exercisable for <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20251231__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zuyHsBybHfX8">3,508,771 shares of our common stock at $0.001 per share. Due to the variability of the conversion feature, it is valued separately from the underlying debt as an embedded conversion feature, which is a derivative liability. Using the Black-Scholes pricing model, we determined the fair value of the derivative liability to be $<span id="xdx_906_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20251231__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zY4OfBg3tXO9">548,321 at inception. The fair value of the derivative liability in excess of the available face value of the note, net of all discounts from other sources, was recorded as a day one financing cost totaling $<span id="xdx_903_eus-gaap--PaymentsOfFinancingCosts_c20251230__20251231__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zvqiWdcLcuAc">192,620. The derivative liability was revalued at January 31, 2026 with an estimated fair value of $<span id="xdx_90A_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_c20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zn2mBDbY46oj">574,278. Accordingly, a loss on change in fair value of derivative liabilities in the amount of $<span id="xdx_908_eus-gaap--DerivativeLossOnDerivative_c20251101__20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_z6TTGu8mJYb9"><span id="xdx_904_eus-gaap--DerivativeLossOnDerivative_c20250801__20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_z3Yp7KTJKqde">25,957 was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended January 31, 2026. See also Note 4. At January 31, 2026, there was $<span id="xdx_90D_eus-gaap--NotesAndLoansPayable_iI_c20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zWP6zX2wVCql" title="Note payable">500,000 of principal, $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zYJ5j2bmTzYb">3,973 of accrued interest, and warrants exercisable for <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260131__us-gaap--SecuritiesFinancingTransactionAxis__custom--MastHillMasterSPANoteMember__us-gaap--DebtInstrumentAxis__custom--TrancheDec2025Member_zu05vvAqKSF3">3,508,771 shares of our common stock outstanding pursuant to the December 31, 2025 tranche. Directors and Officers Promissory Notes At January 31, 2026, we had $100,000 of principal and $32,891 of accrued interest related to these Promissory Notes outstanding and the due date has been extended to <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20260130__20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndOfficersMember_zmKZnz14ao9g" title="Debt maturity date">January 31, 2027. Notes Payable Summary The following notes payable were outstanding: <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zNlpFzo5DiT3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Debt (Details - Notes payable outstanding)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of notes payable outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">January 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">July 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Convertible notes payable, officers and directors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20260131_zfHG13iBVYk6" style="width: 13%; text-align: right" title="Convertible notes payable">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20250731_zTA7u9vkxMid" style="width: 13%; text-align: right" title="Convertible notes payable">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherNotesPayable_iI_c20260131_z0Cg3N4VKXE4" style="text-align: right" title="Notes payable">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OtherNotesPayable_iI_c20250731_zrkN0weIEX3" style="text-align: right" title="Notes payable">300,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20260131__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zJNW9HyjcHZ6" style="border-bottom: Black 1pt solid; text-align: right" title="Notes payable">(4,191</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20250731__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zvhIa2MnozS3" style="border-bottom: Black 1pt solid; text-align: right" title="Notes payable">(512</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Notes payable, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherNotesPayableCurrent_iI_c20260131_zXWKPTZAhrqf" style="text-align: right" title="Notes payable, net">395,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OtherNotesPayableCurrent_iI_c20250731_zq9RS8216dAf" style="text-align: right" title="Notes payable, net">299,488</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConvertibleDebt_iI_c20260131_zfxjNynKtK05" style="text-align: right" title="Convertible notes payable">4,892,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20250731_zUxSyq4hvsxj" style="text-align: right" title="Convertible notes payable">1,584,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20260131__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z7lUi6bPJgN9" style="border-bottom: Black 1pt solid; text-align: right" title="Notes payable">(3,118,556</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_c20250731__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zRM6M7JsTqj9" style="border-bottom: Black 1pt solid; text-align: right" title="Notes payable">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Convertible notes payable, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConvertibleDebtCurrent_iI_c20260131_z1gFZj6wZREj" style="text-align: right" title="Convertible notes payable, net">1,773,691</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConvertibleDebtCurrent_iI_c20250731_zGeHchG6m7Og" style="text-align: right" title="Convertible notes payable, net">1,584,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_pp0p0_c20260131_zAfuOkVNOyX5" style="text-align: right" title="Notes payable">5,392,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--NotesPayable_pp0p0_c20250731_z98oTsGAD3Y5" style="text-align: right" title="Notes payable">1,984,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20260131_zxqjA1hzCNAf" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized debt discount">(3,122,747</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20250731_z6bie1opMjof" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized debt discount">(512</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total notes payable outstanding, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayableCurrent_pp0p0_c20260131_zmioqzS89Ce9" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable current">2,269,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20250731_zIXdpwjQo7Hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable current">1,984,155</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

144000

2000000

891000

294723

300000

2025-08-22

0.18

300000

0.10

2029-08-14

13343

300000

79149

100000

2026-09-30

0.18

100000

0.10

2030-09-30

100000

6067

50000

0.10

30000

2027-01-31

50000

9841

80618 1750

82368

1144000

2026-04-30

499667

21231

14666667

220000

0.10

1000000

22000

190500

647574

507368

225155

422419

223173

1982

424401

220000

9403

1000000

330030 252450 1842002

2262000

0.10

2026-11-13

2242625

2621970

379345

2262000

48339

25000000

0.10

22250000

500000

50000

12500

437500

1538461

495717

137410

516745

21028

469580

3731

1538461

500000

50000

12500

437500

3508771

548321

192620

574278

25957

500000

3973

3508771

100000

32891

2027-01-31

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zNlpFzo5DiT3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Debt (Details - Notes payable outstanding)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of notes payable outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">January 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">July 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Convertible notes payable, officers and directors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20260131_zfHG13iBVYk6" style="width: 13%; text-align: right" title="Convertible notes payable">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NotesPayableRelatedPartiesCurrent_iI_c20250731_zTA7u9vkxMid" style="width: 13%; text-align: right" title="Convertible notes payable">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherNotesPayable_iI_c20260131_z0Cg3N4VKXE4" style="text-align: right" title="Notes payable">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OtherNotesPayable_iI_c20250731_zrkN0weIEX3" style="text-align: right" title="Notes payable">300,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20260131__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zJNW9HyjcHZ6" style="border-bottom: Black 1pt solid; text-align: right" title="Notes payable">(4,191</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20250731__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zvhIa2MnozS3" style="border-bottom: Black 1pt solid; text-align: right" title="Notes payable">(512</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Notes payable, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherNotesPayableCurrent_iI_c20260131_zXWKPTZAhrqf" style="text-align: right" title="Notes payable, net">395,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OtherNotesPayableCurrent_iI_c20250731_zq9RS8216dAf" style="text-align: right" title="Notes payable, net">299,488</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConvertibleDebt_iI_c20260131_zfxjNynKtK05" style="text-align: right" title="Convertible notes payable">4,892,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20250731_zUxSyq4hvsxj" style="text-align: right" title="Convertible notes payable">1,584,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20260131__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z7lUi6bPJgN9" style="border-bottom: Black 1pt solid; text-align: right" title="Notes payable">(3,118,556</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_c20250731__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zRM6M7JsTqj9" style="border-bottom: Black 1pt solid; text-align: right" title="Notes payable">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Convertible notes payable, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConvertibleDebtCurrent_iI_c20260131_z1gFZj6wZREj" style="text-align: right" title="Convertible notes payable, net">1,773,691</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConvertibleDebtCurrent_iI_c20250731_zGeHchG6m7Og" style="text-align: right" title="Convertible notes payable, net">1,584,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_pp0p0_c20260131_zAfuOkVNOyX5" style="text-align: right" title="Notes payable">5,392,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--NotesPayable_pp0p0_c20250731_z98oTsGAD3Y5" style="text-align: right" title="Notes payable">1,984,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20260131_zxqjA1hzCNAf" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized debt discount">(3,122,747</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20250731_z6bie1opMjof" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized debt discount">(512</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total notes payable outstanding, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayableCurrent_pp0p0_c20260131_zmioqzS89Ce9" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable current">2,269,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20250731_zIXdpwjQo7Hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable current">1,984,155</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

100000 100000

400000

300000

4191

512

395809

299488

4892247

1584667

3118556

-0

1773691

1584667

5392247

1984667

3122747

512

2269500

1984155

Note 6. Stock-Based Compensation 2021 Omnibus Stock Incentive Plan At January 31, 2026, <span id="xdx_901_eus-gaap--DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_iI_c20260131__us-gaap--PlanNameAxis__custom--Plan2021Member_zQySMpYCIwre" title="Shares reserved for issuance under plan">17,625,000 shares of our common stock were reserved for issuance pursuant to the 2021 Omnibus Stock Incentive Plan (the “2021 Plan”) and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260131__us-gaap--PlanNameAxis__custom--Plan2021Member_zBYmlgL12Iih" title="Shares remaining under plan">2,500,000 shares remained available for future awards under the 2021 Plan. Stock Options and Restricted Stock Units There was no restricted stock unit activity during the six months ended January 31, 2026. Stock option activity during the six months ended January 31, 2026 was as follows: <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlKEzHmPznmg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details - Stock Option Activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Options outstanding at July 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250801__20260131_zbJTX90TimO1" style="width: 13%; text-align: right" title="Options outstanding, beginning balance">17,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250801__20260131_zsMSFFN4eZaf" style="width: 13%; text-align: right" title="Weighted average exercise price options, beginning balance">0.16</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_iN_di_c20250801__20260131_zYQ6W5vaddR6" style="border-bottom: Black 1pt solid; text-align: right" title="Options cancelled">(2,400,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_iN_di_c20250801__20260131_zvFgX4HEjdaj" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, options cancelled">0.13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Options outstanding at January 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250801__20260131_zkDOS6y9WIZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">14,850,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250801__20260131_zfGwz7lvE594" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price options, ending balance">0.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrants Warrant activity during the six months ended January 31, 2026 was as follows: <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zR2zVx3XPBU7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details - Warrant Activity)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of warrant activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants outstanding at July 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6PpApIyCLX1" style="width: 13%; text-align: right" title="Number of warrants outstanding, beginning balance">21,475,274</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeb7c90pwoe9" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance">0.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVZ2ytrGGEE4" style="text-align: right" title="Number of warrants issued">6,147,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOju0VfIrBRi" style="text-align: right" title="Weighted average exercise price, warrants issued">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zK3I7bL2IKrk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants expired">(470,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziDtUOBK3r0b" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, warrants expired">0.35</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants outstanding at January 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z01hoh6NqKQ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, ending balance">27,152,506</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIVHJi1lKEU1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance">0.20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted average contractual term remaining for outstanding warrants was <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dxL_c20250801__20260131_ztqEZgWycQTj" title="::XDX::P2Y4M17D">2.38 years at January 31, 2026. Unrecognized Stock-Based Compensation Costs At January 31, 2026, we had no unrecognized stock-based compensation.

17625000

2500000

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlKEzHmPznmg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details - Stock Option Activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Options outstanding at July 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250801__20260131_zbJTX90TimO1" style="width: 13%; text-align: right" title="Options outstanding, beginning balance">17,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250801__20260131_zsMSFFN4eZaf" style="width: 13%; text-align: right" title="Weighted average exercise price options, beginning balance">0.16</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod_iN_di_c20250801__20260131_zYQ6W5vaddR6" style="border-bottom: Black 1pt solid; text-align: right" title="Options cancelled">(2,400,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice_iN_di_c20250801__20260131_zvFgX4HEjdaj" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, options cancelled">0.13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Options outstanding at January 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250801__20260131_zkDOS6y9WIZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">14,850,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250801__20260131_zfGwz7lvE594" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price options, ending balance">0.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

17250000

0.16

2400000 -0.13

14850000

0.17

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zR2zVx3XPBU7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details - Warrant Activity)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of warrant activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants outstanding at July 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6PpApIyCLX1" style="width: 13%; text-align: right" title="Number of warrants outstanding, beginning balance">21,475,274</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeb7c90pwoe9" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance">0.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVZ2ytrGGEE4" style="text-align: right" title="Number of warrants issued">6,147,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOju0VfIrBRi" style="text-align: right" title="Weighted average exercise price, warrants issued">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zK3I7bL2IKrk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants expired">(470,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziDtUOBK3r0b" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, warrants expired">0.35</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants outstanding at January 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z01hoh6NqKQ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, ending balance">27,152,506</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250801__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIVHJi1lKEU1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance">0.20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

21475274

0.25

6147232

0.02

470000

0.35

27152506

0.20

Note 7. Common Stock Mast Hill Equity Purchase Agreement Pursuant to an Equity Purchase Agreement (the “Agreement”) dated July 29, 2025, we have the right, but not the obligation, to deliver Put Notices to Mast Hill Fund L.P. to purchase Put Shares of our common stock totaling up to $25.0 million. During the six months ended January 31, 2026, no Put Notices were delivered to Mast Hill under the Agreement. Mast Hill Conversion of Interest and Fees On August 29, 2025, Mast Hill converted $<span id="xdx_90E_ecustom--DebtConversionConvertedInterestAmount1_c20250828__20250829__us-gaap--SecuritiesFinancingTransactionAxis__custom--SPA2022Member_zkp1e5dPsuMl" title="Debt converted, interest converted">80,618 of accrued interest and $1,750 in fees for a total of $82,368 into 1,144,000 shares of our common stock at a conversion price of $0.072 per share. See Note 5. Conversion of LGH Investments, LLC Convertible Note On October 6, 2025, LGH converted $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20251005__20251006__dei--LegalEntityAxis__custom--ConversionOfLGHInvestmentsLLCMember_zy0GWjqvWAJ5" title="Conversion of stock, amount converted">144,000 of principal from its outstanding convertible note into 2,000,000 shares of our common stock at a conversion price of $0.072 per share. As of January 31, 2026, there was $<span id="xdx_906_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20250801__20260131__dei--LegalEntityAxis__custom--ConversionOfLGHInvestmentsLLCMember_zpoWx4XMfyzk" title="Conversion of stock, amount converted">891,000 of principal and $<span id="xdx_905_ecustom--ConversionOfStockInterestConverted1_pp0p0_c20250801__20260131__dei--LegalEntityAxis__custom--ConversionOfLGHInvestmentsLLCMember_zDRJexQRkAwb" title="Conversion of stock, interest converted">294,723 of accrued interest outstanding. See Note 5. Mast Hill Securities Purchase Agreement See Note 5. for a discussion of a November 13, 2025 SPA and related promissory note.

80618 1750

82368

1144000

144000

2000000

891000

294723

Note 8. Net Loss Per Share Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Potentially dilutive common stock and common stock equivalents, including stock options, restricted stock units and warrants are excluded from the diluted loss per share calculation as their inclusion would be antidilutive due to the net loss position. The following anti-dilutive securities were excluded from the calculations of diluted net loss per share: <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zetReRIJBCJ9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss Per Share (Details - Antidilutive shares)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Schedule of anti-dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended January 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended January 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; width: 40%">Options to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_ziZpAuY4Be2f" style="width: 11%; text-align: right" title="Potentially dilutive securities">14,850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zJqflMjcDyr8" style="width: 11%; text-align: right" title="Potentially dilutive securities">17,970,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250801__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zhchCs4J5bk5" style="width: 11%; text-align: right" title="Potentially dilutive securities">14,850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240801__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zyhVEzqqamWd" style="width: 11%; text-align: right" title="Potentially dilutive securities">17,970,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Shares issuable upon conversion of convertible notes and related accrued interest</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zft8WXOQLTy" style="text-align: right" title="Potentially dilutive securities">94,585,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zaaPiAc5gova" style="text-align: right" title="Potentially dilutive securities">26,070,890</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250801__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zTOqFSDGaFP4" style="text-align: right" title="Potentially dilutive securities">94,585,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240801__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zWm2F1pcMHA9" style="text-align: right" title="Potentially dilutive securities">26,070,890</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Warrants to purchase common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3O0MqEqCJhh" style="border-bottom: Black 1pt solid; text-align: right" title="Potentially dilutive securities">27,152,506</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zeyBc49uxaH4" style="border-bottom: Black 1pt solid; text-align: right" title="Potentially dilutive securities">21,475,274</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250801__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zdzRuwcdL0r9" style="border-bottom: Black 1pt solid; text-align: right" title="Potentially dilutive securities">27,152,506</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240801__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zx1Y6IHRs21k" style="border-bottom: Black 1pt solid; text-align: right" title="Potentially dilutive securities">21,475,274</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131_zM5PfqoVuQ0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Potentially dilutive securities">136,588,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131_zYMl3KRDlJG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Potentially dilutive securities">65,516,164</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250801__20260131_zsqdVXa0i5P5" style="border-bottom: Black 2.5pt double; text-align: right" title="Potentially dilutive securities">136,588,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240801__20250131_zaeypTZfNxbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Potentially dilutive securities">65,516,164</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zetReRIJBCJ9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss Per Share (Details - Antidilutive shares)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Schedule of anti-dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended January 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended January 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; width: 40%">Options to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_ziZpAuY4Be2f" style="width: 11%; text-align: right" title="Potentially dilutive securities">14,850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zJqflMjcDyr8" style="width: 11%; text-align: right" title="Potentially dilutive securities">17,970,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250801__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zhchCs4J5bk5" style="width: 11%; text-align: right" title="Potentially dilutive securities">14,850,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240801__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zyhVEzqqamWd" style="width: 11%; text-align: right" title="Potentially dilutive securities">17,970,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Shares issuable upon conversion of convertible notes and related accrued interest</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zft8WXOQLTy" style="text-align: right" title="Potentially dilutive securities">94,585,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zaaPiAc5gova" style="text-align: right" title="Potentially dilutive securities">26,070,890</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250801__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zTOqFSDGaFP4" style="text-align: right" title="Potentially dilutive securities">94,585,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240801__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zWm2F1pcMHA9" style="text-align: right" title="Potentially dilutive securities">26,070,890</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Warrants to purchase common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3O0MqEqCJhh" style="border-bottom: Black 1pt solid; text-align: right" title="Potentially dilutive securities">27,152,506</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zeyBc49uxaH4" style="border-bottom: Black 1pt solid; text-align: right" title="Potentially dilutive securities">21,475,274</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250801__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zdzRuwcdL0r9" style="border-bottom: Black 1pt solid; text-align: right" title="Potentially dilutive securities">27,152,506</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240801__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zx1Y6IHRs21k" style="border-bottom: Black 1pt solid; text-align: right" title="Potentially dilutive securities">21,475,274</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131_zM5PfqoVuQ0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Potentially dilutive securities">136,588,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131_zYMl3KRDlJG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Potentially dilutive securities">65,516,164</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250801__20260131_zsqdVXa0i5P5" style="border-bottom: Black 2.5pt double; text-align: right" title="Potentially dilutive securities">136,588,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240801__20250131_zaeypTZfNxbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Potentially dilutive securities">65,516,164</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

14850000

17970000

14850000

17970000

94585835

26070890

94585835

26070890

27152506

21475274

27152506

21475274

136588341

65516164

136588341

65516164

Note 9. Related Party Transactions Accounts Payable and Accrued Wages, Officers Accounts payable and accrued wages, officers included the following: <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zikyduuP6NCk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details - Accounts payable and accrued wages officers)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 10pt">Schedule of related party payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Reimbursement of expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: 10pt">Joseph M. Redmond, CEO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z2IMj2WISvDe" style="width: 13%; text-align: right" title="Reimbursement of expenses">1,232</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20250731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZi3IHwoIuXc" style="width: 13%; text-align: right" title="Reimbursement of expenses">17,125</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Christine Farrell, CFO</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zpXTc8jDLW9" style="border-bottom: Black 1pt solid; text-align: right" title="Reimbursement of expenses">1,155</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20250731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zb0i2B6BzkPi" style="border-bottom: Black 1pt solid; text-align: right" title="Reimbursement of expenses">34,085</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember_zr7FexV6o563" style="text-align: right" title="Reimbursement of expenses">2,387</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20250731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember_zrdsgZlIupu9" style="text-align: right" title="Reimbursement of expenses">51,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued salary and bonus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 10pt">Joseph M. Redmond, CEO</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20260131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8ELf6eLczXf" style="text-align: right" title="Accrued salary and bonus">1,360,769</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20250731__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJhTNJBKxG9i" style="text-align: right" title="Accrued salary and bonus">1,330,308</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Christine Farrell, CFO</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20260131__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zv4BLL7D2k3f" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued salary and bonus">493,848</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20250731__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zkJh5ka1Txmi" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued salary and bonus">476,925</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_pp0p0_c20260131_zXUw15qQiRR1" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued salary and bonus">1,854,617</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20250731_zWOlfcSnmFei" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued salary and bonus">1,807,233</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedSalariesCurrent_iI_pp0p0_c20260131_zYDUDCTD8td3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable and accrued wages, officers">1,857,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedSalariesCurrent_iI_pp0p0_c20250731_zYSXgcWf8DFe" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable and accrued wages, officers">1,858,443</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> See Note 5 for a discussion of $25,000 Promissory Notes payable to each of our Chief Executive Officer, Chief Financial Officer, and two directors, for an aggregate principal amount of $100,000.

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zikyduuP6NCk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details - Accounts payable and accrued wages officers)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 10pt">Schedule of related party payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Reimbursement of expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: 10pt">Joseph M. Redmond, CEO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z2IMj2WISvDe" style="width: 13%; text-align: right" title="Reimbursement of expenses">1,232</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20250731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZi3IHwoIuXc" style="width: 13%; text-align: right" title="Reimbursement of expenses">17,125</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Christine Farrell, CFO</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zpXTc8jDLW9" style="border-bottom: Black 1pt solid; text-align: right" title="Reimbursement of expenses">1,155</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20250731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zb0i2B6BzkPi" style="border-bottom: Black 1pt solid; text-align: right" title="Reimbursement of expenses">34,085</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember_zr7FexV6o563" style="text-align: right" title="Reimbursement of expenses">2,387</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20250731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember_zrdsgZlIupu9" style="text-align: right" title="Reimbursement of expenses">51,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued salary and bonus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 10pt">Joseph M. Redmond, CEO</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20260131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8ELf6eLczXf" style="text-align: right" title="Accrued salary and bonus">1,360,769</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20250731__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJhTNJBKxG9i" style="text-align: right" title="Accrued salary and bonus">1,330,308</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Christine Farrell, CFO</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20260131__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zv4BLL7D2k3f" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued salary and bonus">493,848</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20250731__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zkJh5ka1Txmi" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued salary and bonus">476,925</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_pp0p0_c20260131_zXUw15qQiRR1" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued salary and bonus">1,854,617</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AccruedSalariesCurrentAndNoncurrent_pp0p0_c20250731_zWOlfcSnmFei" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued salary and bonus">1,807,233</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedSalariesCurrent_iI_pp0p0_c20260131_zYDUDCTD8td3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable and accrued wages, officers">1,857,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedSalariesCurrent_iI_pp0p0_c20250731_zYSXgcWf8DFe" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable and accrued wages, officers">1,858,443</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1232

17125

1155

34085

2387

51210

1360769

1330308

493848

476925

1854617

1807233

1857004

1858443

25000

false false false false